A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 79-83

  Sirotnak, F M ^a   Sepp Lorenzino, Laura ^a   Kohl, Nancy E ^b   Rosen, Neal ^a   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Human prostate tumors; Protein farnesylation inhibitor

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 0033934641     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000126     Document Type: Article

References (20)

1. 1. DeFeo D, Gonda MA, Young HA, Chang EH, Lowry DR (1981) Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci USA 78: 3328-3332
2. 2. Shah C, Weinberg RA (1982) Isolation of a transforming sequence from a human bladder cancer carcinoma cell line. Cell 29: 161-169
3. N-ras expression. EMBO J 5: 2617-2621
4. 4. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P (1987) Coexpression of MMTV/v-H-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49: 465-475
5. 5. Mangues R, Seidman I, Gordon JW, Pelicer A (1992) Overexpression of the V-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. Oncogene 7: 2073-2076
6. 6. Schafer WR, Kim R, Sterne RE, Thorner J, Kim SH, Rine J (1989) Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 254:379-385
7. 7. Hancock JF, Magee AI, Childs JE, Marshall CJ (1989) All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177
8. 8. Kohl NE, Mosser SD, deSolms SJ, Grulsani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937
9. 9. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Masters JC (1993) Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260: 1937-1942
10. 10. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Walter KA, Nomeir AA, Lin C-C, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Cation JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR (1998) Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human xenograft models and wap-ras transgenic mice. Cancer Res 58: 4947-4956
11. 11. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N (1995) A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage dependent and independent growth of human tumor cells lines. Cancer Res 55: 5302-5309
12. 12. Carter BS, Epstein JI, Isaacs WB (1990) ras gene mutations in human prostate cancer. Cancer Res 50: 6830-6832
13. 13. Kohl NE, Wilson FR, Mosser SD, Guiliani EA, DeSolma SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A (1994) Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145
14. 14. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolma SJ, Guiliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Kral AM, Miller PJ, Mosses SD, O'Neill TJ, Randa E, Schaner MD, Gibbs JB, Oliff A (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1: 792-797
15. 15. Mangues R, Coral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A (1998) Antitumor effects of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors over expressing N-ras in transgenic mice. Cancer Res 58: 1253-1259
16. 16. Chou T-C, Otter GM, Sirotnak FM (1996) Schedule-dependent synergism of Taxol and Taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37: 222-228
17. 17. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42: 313-318
18. 18. Zar JH, Biostatistical analysis, 2nd edn. Prentice Hall, Englewood Cliffs, pp 145-146
19. 19. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su Dai-Shi, Danishesfesky SJ, Rosen N (1998) Farnesyl transferase inhibitors cause enhanced sensitivity to Taxol and epithilones. Proc Natl Acad Sci USA 95: 1369-1374
20. 1 block in p53 wild-type tumor cells. J Biol Chem 273: 20243-20251